Your browser doesn't support javascript.
loading
Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.
Reis, Laise Rodrigues; Costa-Rocha, Ismael Artur; Abdala-Torres, Thais; Campi-Azevedo, Ana Carolina; Peruhype-Magalhães, Vanessa; Araújo, Márcio Sobreira Silva; Spezialli, Elaine; do Valle Antonelli, Lis Ribeiro; da Silva-Pereira, Rosiane Aparecida; Almeida, Gregório Guilherme; Fernandes, Eder Gatti; Fantinato, Francieli Fontana Sutile Tardetti; Domingues, Carla Magda Allan Santos; Lemos, Maria Cristina Ferreira; Chieppe, Alexandre; Lemos, Jandira Aparecida Campos; Coelho-Dos-Reis, Jordana Grazziela; de Lima, Sheila Maria Barbosa; de Souza Azevedo, Adriana; Schwarcz, Waleska Dias; Camacho, Luiz Antônio Bastos; de Lourdes de Sousa Maia, Maria; de Noronha, Tatiana Guimarães; Duault, Caroline; Rosenberg-Hasson, Yael; Teixeira-Carvalho, Andréa; Maecker, Holden Terry; Martins-Filho, Olindo Assis.
Affiliation
  • Reis LR; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Costa-Rocha IA; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Abdala-Torres T; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Campi-Azevedo AC; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
  • Peruhype-Magalhães V; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Araújo MSS; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Spezialli E; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • do Valle Antonelli LR; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • da Silva-Pereira RA; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Almeida GG; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Fernandes EG; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Fantinato FFST; Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil.
  • Domingues CMAS; Departamento de Vigilância das Doenças Transmissíveis, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, DF, Brazil.
  • Lemos MCF; External Consultant, Independent Researcher, Brasília, DF, Brazil.
  • Chieppe A; Secretaria de Estado de Saúde, Rio de Janeiro, RJ, Brazil.
  • Lemos JAC; Superintendência de Vigilância em Saúde, Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • Coelho-Dos-Reis JG; Secretaria Municipal de Saúde de Belo Horizonte, Belo Horizonte, MG, Brazil.
  • de Lima SMB; Laboratório de Virologia Básica e Aplicada, Instituto de Ciências Biológicas da Universidade Federal de Minas Gerais - UFMG, Belo Horizonte, MG, Brazil.
  • de Souza Azevedo A; Departamento de Desenvolvimento Experimental e Pré-Clínico, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • Schwarcz WD; Laboratório de Análise Imunomolecular, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • Camacho LAB; Laboratório de Análise Imunomolecular, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • de Lourdes de Sousa Maia M; Escola Nacional de Saúde Pública - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • de Noronha TG; Assessoria Clínica, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • Duault C; Assessoria Clínica, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • Rosenberg-Hasson Y; Human Immune Monitoring Center, Stanford University, Stanford, CA, USA.
  • Teixeira-Carvalho A; Human Immune Monitoring Center, Stanford University, Stanford, CA, USA.
  • Maecker HT; Instituto René Rachou, Fundação Oswaldo Cruz - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil.
  • Martins-Filho OA; Human Immune Monitoring Center, Stanford University, Stanford, CA, USA. maecker@stanford.edu.
Sci Rep ; 14(1): 7709, 2024 04 02.
Article in En | MEDLINE | ID: mdl-38565882
ABSTRACT
The present study aimed at evaluating the YF-specific neutralizing antibody profile besides a multiparametric analysis of phenotypic/functional features of cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF vaccine, administered as a single subcutaneous injection. The immunological parameters of each volunteer was monitored at two time points, referred as before (Day 0) [Non-Vaccinated, NV(D0)] and after vaccination (Day 30-45) [Primary Vaccinees, PV(D30-45)]. Data demonstrated high levels of neutralizing antibodies for PV(D30-45) leading to a seropositivity rate of 93%. A broad increase of systemic soluble mediators with a mixed profile was also observed for PV(D30-45), with IFN-γ and TNF-α presenting the highest baseline fold changes. Integrative network mapping of soluble mediators showed increased correlation numbers in PV(D30-45) as compared to NV(D0) (532vs398). Moreover, PV(D30-45) exhibited increased levels of Terminal Effector (CD45RA+CCR7-) CD4+ and CD8+ T-cells and Non-Classical memory B-cells (IgD+CD27+). Dimensionality reduction of Mass Cytometry data further support these findings. A polyfunctional cytokine profile (TNF-α/IFN-γ/IL-10/IL-17/IL-2) of T and B-cells was observed upon in vitro antigen recall. Mapping and kinetics timeline of soluble mediator signatures for PV(D30-45) further confirmed the polyfunctional profile upon long-term in vitro culture, mediated by increased levels of IFN-γ and TNF-α along with decreased production of IL-10. These findings suggest novel insights of correlates of protection elicited by the 1/5 fractional dose of 17DD-YF vaccine.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Yellow Fever / Yellow Fever Vaccine Limits: Adult / Humans Language: En Journal: Sci Rep Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Yellow Fever / Yellow Fever Vaccine Limits: Adult / Humans Language: En Journal: Sci Rep Year: 2024 Document type: Article Affiliation country: